Fullerene‐Based Immunoregulatory Nanomaterials for Immunotherapy of Tumor and Immune‐Related Inflammatory Diseases
Source abstract
Abstract
Abstract Immunoregulatory strategies for activating or inhibiting immune responses have emerged as a promising approach for treating tumors and immune‐related inflammatory diseases. Nanomaterials, also known for their inherent immunoregulatory capacity, are extensively investigated for their potential in immunotherapy. Among these immunoregulatory nanomaterials, fullerene‐based nanomaterials with unique immunoregulatory properties have attracted considerable attention for their use in immunotherapy. In this study, a comprehensive review of the recent research progress on fullerene‐based immunoregulatory nanomaterials is presented. It illustrates the specific mechanism of immune activation using fullerene nanomaterials and reviews their applications in tumor immunotherapy and tumor‐enhancement immunotherapy. Now It introduces the molecular mechanism of fullerene nanomaterials for inhibiting over‐activated inflammation. Herein, different negative immunoregulatory strategies are developed using fullerene nanomaterials to inhibit immune‐related inflammatory diseases. Additionally, the current challenges and prospects for developing efficient clinical usage of fullerene‐based immunoregulatory nanomaterials are discussed.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics · Fullerene Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Beijing National Laboratory for Molecular Sciences Key Laboratory of Molecular Nanostructure and Nanotechnology Institute of Chemistry Chinese Academy of Sciences Beijing 100190 China
University of Chinese Academy of Sciences Beijing 100049 China
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China · State Key Laboratory of Drug Research, Chinese Academy of Sciences
References (100+)
Show source-provided references
1. 10.1016/j.cell.2015.02.01010.1016/j.cell.2015.02.010 ↗
2. 10.1038/s41586-022-05254-310.1038/s41586-022-05254-3 ↗
3. 10.1016/j.immuni.2019.12.01110.1016/j.immuni.2019.12.011 ↗
4. 10.1038/nri392110.1038/nri3921 ↗
5. 10.1126/science.aar331810.1126/science.aar3318 ↗
6. 10.1016/j.cmet.2016.01.00310.1016/j.cmet.2016.01.003 ↗
7. 10.1126/sciadv.adn213610.1126/sciadv.adn2136 ↗
8. 10.1056/NEJMra230229110.1056/NEJMra2302291 ↗
9. 10.1038/nrcardio.2016.18510.1038/nrcardio.2016.185 ↗
10. 10.1016/j.cell.2016.11.01810.1016/j.cell.2016.11.018 ↗
11. 10.1016/j.cell.2018.12.01210.1016/j.cell.2018.12.012 ↗
12. 10.1146/annurev-immunol-051116-05235810.1146/annurev-immunol-051116-052358 ↗
13. 10.1016/j.it.2021.11.00910.1016/j.it.2021.11.009 ↗
14. 10.1126/science.120348610.1126/science.1203486 ↗
15. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
16. 10.1016/S0140-6736(23)02747-210.1016/S0140-6736(23)02747-2 ↗
17. 10.1016/S0140-6736(23)01126-110.1016/S0140-6736(23)01126-1 ↗
18. 10.1186/s13045-019-0746-110.1186/s13045-019-0746-1 ↗
19. 10.1016/j.trecan.2017.01.00410.1016/j.trecan.2017.01.004 ↗
20. 10.1038/s41577-019-0269-610.1038/s41577-019-0269-6 ↗
21. Ni K. · Nat. Commun. · 2018 · 9
22. 10.1038/s41577-021-00539-610.1038/s41577-021-00539-6 ↗
23. 10.1038/s41577-020-0306-510.1038/s41577-020-0306-5 ↗
24. 10.1016/S1473-3099(19)30567-510.1016/S1473-3099(19)30567-5 ↗
25. 10.1038/s41584-023-01063-810.1038/s41584-023-01063-8 ↗
26. 10.1038/s41584-018-0074-910.1038/s41584-018-0074-9 ↗
27. 10.1126/sciadv.adl047910.1126/sciadv.adl0479 ↗
28. 10.1038/s41570-018-0023-910.1038/s41570-018-0023-9 ↗
29. 10.1126/sciadv.aay160110.1126/sciadv.aay1601 ↗
30. 10.1038/s41586-021-04243-210.1038/s41586-021-04243-2 ↗
31. 10.1021/acsnano.3c0385710.1021/acsnano.3c03857 ↗
32. 10.1021/nn401196a10.1021/nn401196a ↗
33. 10.1126/science.122633810.1126/science.1226338 ↗
34. 10.1126/sciadv.abc782810.1126/sciadv.abc7828 ↗
35. 10.1016/j.ccell.2022.01.00610.1016/j.ccell.2022.01.006 ↗
36. 10.1126/sciadv.abq369910.1126/sciadv.abq3699 ↗
37. 10.1002/adma.20240296810.1002/adma.202402968 ↗
38. 10.1002/adma.20180830310.1002/adma.201808303 ↗
39. 10.1016/j.semcancer.2022.01.00810.1016/j.semcancer.2022.01.008 ↗
40. 10.1186/s13045-021-01096-010.1186/s13045-021-01096-0 ↗
41. 10.1021/acsnano.1c0062910.1021/acsnano.1c00629 ↗
42. 10.1039/C7CS00748E10.1039/C7CS00748E ↗
43. 10.1021/acsami.7b0471810.1021/acsami.7b04718 ↗
44. 10.1039/C8TB01097H10.1039/C8TB01097H ↗
45. 10.1021/nn901478z10.1021/nn901478z ↗
46. 10.1016/j.jconrel.2020.01.05310.1016/j.jconrel.2020.01.053 ↗
47. 10.31635/ccschem.024.20230351710.31635/ccschem.024.202303517 ↗
48. 10.1021/acsami.3c1616810.1021/acsami.3c16168 ↗
49. 10.1002/adma.20231244010.1002/adma.202312440 ↗
50. 10.1073/pnas.231167312010.1073/pnas.2311673120 ↗
51. 10.1126/sciadv.abc158610.1126/sciadv.abc1586 ↗
52. 10.1038/s41571-024-00859-110.1038/s41571-024-00859-1 ↗
53. 10.1038/s41563-018-0091-810.1038/s41563-018-0091-8 ↗
54. 10.1002/smll.20120154610.1002/smll.201201546 ↗
55. 10.1038/s41392-023-01452-110.1038/s41392-023-01452-1 ↗
56. 10.1021/acs.nanolett.0c0128710.1021/acs.nanolett.0c01287 ↗
57. 10.1002/advs.20230291010.1002/advs.202302910 ↗
58. 10.1038/nrclinonc.2018.2710.1038/nrclinonc.2018.27 ↗
59. Zhu X. · Mol. Cancer · 2023 · 22
60. 10.1016/j.immuni.2014.06.01010.1016/j.immuni.2014.06.010 ↗
61. 10.1038/nrclinonc.2016.21710.1038/nrclinonc.2016.217 ↗
62. 10.1186/s13045-019-0760-310.1186/s13045-019-0760-3 ↗
63. 10.3390/ijms2213699510.3390/ijms22136995 ↗
64. 10.1038/ni.193710.1038/ni.1937 ↗
65. 10.1002/adhm.20180052510.1002/adhm.201800525 ↗
66. 10.1007/s12274-023-6266-x10.1007/s12274-023-6266-x ↗
67. 10.1016/j.nantod.2022.10170210.1016/j.nantod.2022.101702 ↗
68. 10.1007/s40820-021-00622-610.1007/s40820-021-00622-6 ↗
69. 10.1016/j.scib.2023.06.03110.1016/j.scib.2023.06.031 ↗
70. 10.1002/adhm.20230130610.1002/adhm.202301306 ↗
71. 10.1126/science.110481910.1126/science.1104819 ↗
72. 10.1073/pnas.202005711810.1073/pnas.2020057118 ↗
73. 10.1038/nrclinonc.2018.2910.1038/nrclinonc.2018.29 ↗
74. 10.3390/ijms2405442210.3390/ijms24054422 ↗
75. 10.1126/science.aaw787510.1126/science.aaw7875 ↗
76. 10.1016/j.biomaterials.2019.05.02910.1016/j.biomaterials.2019.05.029 ↗
77. 10.1039/C9TB02752A10.1039/C9TB02752A ↗
78. 10.1038/s41423-019-0315-010.1038/s41423-019-0315-0 ↗
79. 10.1016/j.immuni.2010.05.00710.1016/j.immuni.2010.05.007 ↗
80. 10.1038/s41581-019-0110-210.1038/s41581-019-0110-2 ↗
81. 10.1016/j.cmet.2021.10.00410.1016/j.cmet.2021.10.004 ↗
82. 10.1016/j.immuni.2020.06.01710.1016/j.immuni.2020.06.017 ↗
83. 10.1038/nri342310.1038/nri3423 ↗
84. 10.1016/j.cell.2010.02.04310.1016/j.cell.2010.02.043 ↗
85. 10.1021/acsnano.3c0939710.1021/acsnano.3c09397 ↗
86. 10.1038/nri343010.1038/nri3430 ↗
87. 10.1161/CIRCRESAHA.118.31323410.1161/CIRCRESAHA.118.313234 ↗
88. 10.1038/s41577-019-0198-410.1038/s41577-019-0198-4 ↗
89. 10.1146/annurev-immunol-070119-11510410.1146/annurev-immunol-070119-115104 ↗
90. 10.1186/s40779-017-0122-910.1186/s40779-017-0122-9 ↗
91. 10.1002/eji.20184780710.1002/eji.201847807 ↗
92. 10.1038/s41575-019-0157-310.1038/s41575-019-0157-3 ↗
93. 10.7150/thno.8571110.7150/thno.85711 ↗
94. 10.1039/D3TB00714F10.1039/D3TB00714F ↗
95. 10.1038/nri360810.1038/nri3608 ↗
96. 10.1126/science.aat083510.1126/science.aat0835 ↗
97. 10.1053/j.gastro.2016.07.00810.1053/j.gastro.2016.07.008 ↗
98. 10.1016/j.immuni.2019.05.02110.1016/j.immuni.2019.05.021 ↗
99. 10.1038/nrgastro.2016.16910.1038/nrgastro.2016.169 ↗
100. 10.1038/nri373810.1038/nri3738 ↗